Intra-Cellular Therapies Inc. (ITCI) said that it has priced its underwritten public offering of 6.85 million shares of its common stock at a public offering price of $73.00 per share.
ITCI closed Wednesday's regular trading at $76.69 down $3.15 or 3.95%. In the after-hours trading, the stock further dropped $0.99 or 1.29%.
The company expects gross proceeds from the offering to be $500.0 million before deducting underwriting discounts and commissions and offering expenses.
Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1.03 million shares on the same terms and conditions.
The offering is expected to close on April 22, 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.